NEW YORK (GenomeWeb News) – With uncertainty over future National Institutes of Health funding and concerns over austerity measures in Europe, investors have recently cooled on the stocks of genomics tools firms.

Following a strong January and modest gains for the remainder of the first quarter, the stocks of genomics tools firms and some molecular diagnostics companies have slumped over the past couple of months, though part of that can be attributed to bearish trends in the broader stock market.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Genome Research this week: multiplex genotyping of germline and somatic short tandem repeats, graph-based regularization, and more.

A lack of funding may lead more than two dozen research facilities in Australia to shut down in three months.

Researchers report that paternally inherited genes are more likely to be expressed in mice.

The US Supreme Court has declined to review a decision involving the use of "inadvertently shed" DNA in a police investigation and subsequent conviction.